EVAX on Nasdaq

Evaxion A/S

Evaxion A/S is a biological products company, listed on Nasdaq (EVAX).1

Price unavailable

Last updated Oct 20, 2026.

Overview

$7.5MRevenue, fiscal 20252
-$7.7MNet income, fiscal 20252

Compare with Solid Biosciences Inc., Fate Therapeutics or Eloxx Pharmaceuticals, Inc., or pick any stock.

  • TickerEVAX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersG71
  • Incorporated inDenmark3
  • Business addressDr Neergaards Vej 5F, Hoersholm3
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

We were organized under the laws of the Kingdom of Denmark in August 2008 as a private limited liability company (Anpartsselskab, or ApS) and then transformed into a public limited liability company (Aktieselskab, or A/S), effective April 9, 2019. Prior to the transformation, on April 1, 2014, our legal name changed from Novvac ApS to Evaxion Biotech ApS. April 20, 2025, our legal name changed from Evaxion Biotech A/S to Evaxion A/S. We commenced operations in August 2008.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-122.7%Operating margin2
-102.4%Net margin2
125.1%Revenue growth, 20252
-45.2%Return on equity2
0.31×Debt to equity2
-$6.6MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development92¢$10.0M
  • Income tax8¢$908.0K

Out of $7.5M in revenue.2 The company lost money this year.

Financial statements

Revenue52$7.5M in 2025
0$2.0M$4.0M$6.0M$8.0M2022: $0$020222023: $73.0K$73.0K20232024: $3.3M$3.3M2024+4481%2025: $7.5M$7.5M2025+125%
Operating income678952-$9.2M in 2025+64% since 2018
-$30.0M-$20.0M-$10.0M02018: -$5.6M-$5.6M20182019: -$10.9M-$10.9M2019+93%2020: -$16.6M-$16.6M2020+53%2021: -$25.8M-$25.8M2021+56%2022: -$25.3M-$25.3M2022−2%2023: -$22.2M-$22.2M2023−12%2024: -$14.7M-$14.7M2024−34%2025: -$9.2M-$9.2M2025−37%
Net income678952-$7.7M in 2025+39% since 2018
-$30.0M-$20.0M-$10.0M02018: -$5.5M-$5.5M20182019: -$11.2M-$11.2M2019+102%2020: -$15.0M-$15.0M2020+34%2021: -$24.5M-$24.5M2021+63%2022: -$23.2M-$23.2M2022−6%2023: -$22.1M-$22.1M2023−5%2024: -$10.6M-$10.6M2024−52%2025: -$7.7M-$7.7M2025−27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenue$7.5M$3.3M$73.0K
Research and development-$10.0M-$10.5M-$11.9M
General and administrative-$6.8M-$7.6M-$10.4M
Operating loss-$9.2M-$14.7M-$22.2M
Finance income$4.6M$6.5M$963.0K
Finance expenses-$4.0M-$3.1M-$1.7M
Net loss before tax-$8.6M-$11.4M-$22.9M
Total income tax benefit for the year$908.0K$788.0K$790.0K
Net loss for the year-$7.7M-$10.6M-$22.1M
Net loss attributable to shareholders of Evaxion A/S-$7.7M-$10.6M-$22.1M
Exchange differences on translation of foreign operations$0-$14.0K-$57.0K
Exchange rate adjustments of investments in subsidiaries-$41.0K-$5.0K$3.0K
Exchange differences on currency translation to presentation currency$406.0K$197.0K-$68.0K
Other comprehensive income/(loss) for the year, net of tax$365.0K$178.0K-$122.0K
Total comprehensive loss-$7.3M-$10.4M-$22.2M
Total comprehensive loss attributable to shareholders of Evaxion A/S-$7.3M-$10.4M-$22.2M
Loss per share before and after dilution (in dollars per share)-$0.02-$0.20-$0.81

Compare Evaxion A/S with another company

Corporate structure

Evaxion A/S sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Evaxion A/S

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Evaxion A/S, latest May 15, 2025 (3 filings since Nov 14, 2024)
  • Evaxion A/S G7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Evaxion A/S reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$3.3M2 Dec 31, 2025$3.5M2 Dec 31, 2024−5.5%
Operating-lease assets (leased space)$1.7M2 Dec 31, 2025$1.7M2 Dec 31, 2024−2.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$23.2M2 Dec 31, 2025$6.0M2 Dec 31, 2024+290.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$02 Dec 31, 2025$05 Dec 31, 2024

Leadership

Who has led Evaxion A/S, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. A/s Evaxion2026
  2. Helen Katrina Tayton-Martin2026–now

Chief financial officer

  1. A/s Evaxion2026–now
Board members and other officers (9)

Former names

  • Evaxion Biotech A/SOct 22, 2020 to May 5, 20253

Timeline

  1. Mar 31, 2026New chief executive Helen Katrina Tayton-Martin becomes CEO11
  2. Mar 18, 2026New chief executive A/s Evaxion becomes CEO10

Calendar

Coming up

  1. Nov 19, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.73 a share, on Nov 6, 2025.22

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

315 filings to the SEC since October 2021: 5 annual reports, 16 insider forms, 6 large holders, 288 other. The latest 20:

  1. Oct 2, 20266-K EDGAR
  2. Sep 14, 20266-K EDGAR
  3. Sep 4, 20266-K EDGAR
  4. Aug 20, 20266-K EDGAR
  5. Aug 20, 20266-K EDGAR
  6. Aug 17, 20266-K EDGAR
  7. Aug 14, 20266-K EDGAR
  8. Jul 17, 20266-K EDGAR
  9. Jul 13, 20266-K EDGAR
  10. Jul 1, 20266-K EDGAR
  11. Jun 12, 20266-K EDGAR
  12. Jun 11, 20266-K EDGAR
  13. May 12, 20266-K EDGAR
  14. May 7, 20266-K EDGAR
  15. May 4, 20266-K EDGAR
  16. Apr 27, 20266-K EDGAR
  17. Apr 24, 20263 OWNERSHIP DOCUMENT EDGAR
  18. Apr 22, 20266-K EDGAR
  19. Apr 17, 20266-K EDGAR
  20. Apr 17, 20266-K EDGAR

The 315 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Merck & Co., Inc.1,214,126$3.8M0.7%New
Ikarian Capital, LLC74,698$231.6K0.0%No change
Rathbones Group PLC45,723$141.7K0.0%−45,723
Citadel Advisors LLC36,584$113.4K0.0%+18,811
Renaissance Technologies LLC33,800$104.8K0.0%−5,425
Annis Gardner Whiting Capital Advisors, LLC30,000$93.0K0.0%No change
J. Safra Sarasin Holding AG22,896$71.0K0.0%New
Rhumbline Advisers21,849$67.7K0.0%+190
Jane Street Group, LLC20,581$63.8K0.0%New
Boothbay Fund Management, LLC18,426$57.1K0.0%No change
Stonepine Capital Management, LLC17,562$54.4K0.0%−2,151
SmartHarvest Portfolios, LLC13,460$41.7K0.0%−348
XTX Topco Ltd12,899$40.0K0.0%−9,154
Wesbanco Bank Inc10,000$31.0K0.0%No change
Northwestern Mutual Wealth Management Co8,000$24.8K0.0%No change
UBS Group AG6,275$19.5K0.0%New
GAMMA Investing LLC4,612$14.3K0.0%−586
Integrated Wealth Concepts LLC642$2.0K0.0%New
SBI Securities Co., Ltd.62$1920.0%No change
Bessemer Group Inc18$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Evaxion A/S is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREvaxion A/S1
  • CIK0001828253
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inDenmark4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressDr Neergaards Vej 5F, Hoersholm, Denmark1
  • Phone45526565541
  • Shares outstanding417,010,756 shares as of Dec 31, 20254
  • AuditorEY Godkendt Revisionspartnerselskab, Copenhagen, Denmark PCAOB ID 1757; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceOct 22, 20201
  • Filings358 in all: 6-K (238), CORRESP (15), F-1/A (13), UPLOAD (11), 3 (9), EFFECT (9), 6-K/A (8), 3/A (7)1
    All 25 form types

    424B4 (7), F-1 (7), 20-F (6), DRSLTR (5), 424B5 (3), DRS/A (3), SCHEDULE 13G/A (3), DRS (2), F-3 (2), SC 13G (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), F-1MEF (1), POS AM (1), S-8 (1), SC 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 5, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing fifty ordinary shares, nominal value DKK 0.25 per shareEVAXThe Nasdaq Stock Market LLC
Ordinary Shares, nominal value of DKK 0.25 per shareThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 5, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23